Evelo Biosciences, Inc.
EVLO
$0.0003
-$0.0002-40.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -82.35M | -100.55M | -110.01M | -114.53M | -119.64M |
| Total Depreciation and Amortization | 1.56M | 1.88M | 1.99M | 2.06M | 2.08M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.87M | 19.32M | 19.01M | 20.90M | 20.22M |
| Change in Net Operating Assets | -11.79M | -6.53M | -3.57M | -9.67M | -8.55M |
| Cash from Operations | -73.70M | -85.88M | -92.58M | -101.24M | -105.89M |
| Capital Expenditure | -287.00K | -249.00K | -481.00K | -622.00K | 49.00K |
| Sale of Property, Plant, and Equipment | 560.00K | -- | -- | -- | 32.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 273.00K | -249.00K | -481.00K | -622.00K | 81.00K |
| Total Debt Issued | 44.49M | 44.49M | 44.49M | 44.49M | 0.00 |
| Total Debt Repaid | -52.66M | -47.61M | -47.61M | -47.61M | -- |
| Issuance of Common Stock | 29.20M | 5.56M | 84.69M | 84.78M | 79.92M |
| Repurchase of Common Stock | -- | -- | -- | -- | -126.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -272.00K | -235.00K | -223.00K | 0.00 | 0.00 |
| Cash from Financing | 20.76M | 2.21M | 81.34M | 81.66M | 79.79M |
| Foreign Exchange rate Adjustments | 518.00K | -455.00K | -437.00K | -454.00K | -1.02M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -52.15M | -84.38M | -12.16M | -20.66M | -27.04M |